| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.05 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.096 | 0.05 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.06 | 0.06 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.06 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.099 | 0.07 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.058 | 0.07 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |